Topics

Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting

12:46 EST 28 Nov 2018 | Investing News Network

Pluristem Therapeutics (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will present data from the first cohort of its Phase I study of PLX-R18 cells for the treatment of incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT) at the American Society of Hematology’s (ASH) 60th Annual Meeting to be … Continued

The post Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting appeared first on Investing News Network.

Original Article: Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting

NEXT ARTICLE

More From BioPortfolio on "Pluristem to Present First Cohort Data from PLX-R18 Hematological Study at ASH Annual Meeting"

Quick Search

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...